Form 4: Exagen Inc. CEO John Aballi Acquires Shares Through Employee Stock Purchase Plan
SEC Form 4 Filing
Exagen Inc.'s CEO, John Aballi, reports the acquisition of company shares through the Employee Stock Purchase Plan (ESPP).
Summary
- On February 28, 2025, John Aballi, the President and CEO of Exagen Inc., acquired 8,621 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $2.465 per share.
- Following this transaction, Aballi directly owns 746,214 shares of Exagen Inc.
- Additionally, Aballi indirectly owns 40,401 shares through his spouse.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reports a routine transaction. The CEO's participation in the ESPP is a mildly positive signal, but the filing itself is a standard regulatory requirement.
Positives
- The CEO's participation in the ESPP demonstrates confidence in the company's future.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be a signal to investors.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased investment in the company.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of transaction: Acquisition of common stock through ESPP |
| 03/04/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.